Effective treatment of experimental autoimmune neuritis with human immunoglobulin

Journal of the Neurological Sciences

Volumn 256, Issue 1-2, 2007, Pages 61-67

  Lin, Hsin Hsin ^a   Spies, Judith M ^a,b   Lu, Jun Lan ^c   Pollard, John D ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Electrophysiology; Experimental autoimmune neuritis; Histology; Inflammatory demyelinating neuropathy; Intravenous immunoglobulin

Indexed keywords

HUMAN IMMUNOGLOBULIN;

AMPLITUDE MODULATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DEMYELINATING NEUROPATHY; DISEASE COURSE; DISEASE DURATION; DRUG MEGADOSE; ELECTROPHYSIOLOGY; EVOKED SOMATOSENSORY RESPONSE; EXPERIMENTAL AUTOIMMUNE NEURITIS; GUILLAIN BARRE SYNDROME; HIP; HISTOPATHOLOGY; INFLAMMATORY DEMYELINATING NEUROPATHY; MALE; MORPHOLOGY; MOTOR NERVE; MUSCLE EXCITATION; NERVE CONDUCTION; NEURITIS; NONHUMAN; PRIORITY JOURNAL; RAT; TREATMENT DURATION;

ACTION POTENTIALS; ANIMALS; DISEASE MODELS, ANIMAL; ELECTROMYOGRAPHY; EVOKED POTENTIALS, SOMATOSENSORY; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; NEURAL CONDUCTION; NEURITIS, AUTOIMMUNE, EXPERIMENTAL; RATS; RATS, INBRED LEW; REACTION TIME; TOLONIUM CHLORIDE;

EID: 34147092202     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2007.02.017     Document Type: Article

References (43)

1. Hartung H.P., Pollard J.D., Harvey G.K., and Toyka K.V. Immunopathogenesis and treatment of the Guillain-Barré syndrome-Part I. Muscle Nerve 18 2 (Feb 1995) 137-153
2. Hartung H.P., van der Meché F.G., and Pollard J.D. Guillain-Barré syndrome, CIDP and other chronic immune-mediated neuropathies. Curr Opin Neurol 11 5 (Oct 1998) 497-513
3. Mäurer M., and Gold R. Animal models of immune-mediated neuropathies. Curr Opin Neurol 15 5 (Oct 2002) 617-622
4. Gold R., Hartung H.P., and Toyka K.V. Animal models for autoimmune demyelinating disorders of the nervous system. Mol Med Today 6 2 (Feb 2000) 88-91
5. Hartung H.P., and Toyka K.V. T-cell and macrophage activation in experimental autoimmune neuritis and Guillain-Barré syndrome. Ann Neurol 27 Suppl (1990) S57-S63
6. Ho T.W., McKhann G.M., and Griffin J.W. Human autoimmune neuropathies. Annu Rev Neurosci 21 (1998) 187-226
7. Zhu J., Mix E., and Link H. Cytokine production and the pathogenesis of experimental autoimmune neuritis and Guillain-Barré syndrome. J Neuroimmunol 84 1 (Apr 1 1998) 40-52
8. Fujioka T., Purev E., and Rostami A. Chemokine mRNA expression in the cauda equina of Lewis rats with experimental allergic neuritis. J Neuroimmunol 97 1-2 (Jun 1 1999) 51-59
9. Kieseier B.C., Krivacic K., Jung S., Pischel H., Toyka K.V., Ransohoff R.M., et al. Sequential expression of chemokines in experimental autoimmune neuritis. J Neuroimmunol 110 1-2 (Oct 2 2000) 121-129
10. Stoll G., Wesemeier C., Gold R., Solymosi L., Toyka K.V., and Bendszus M. In vivo monitoring of macrophage infiltration in experimental autoimmune neuritis by magnetic resonance imaging. J Neuroimmunol 149 1-2 (Apr 2004) 142-146
11. Kiefer R., Kieseier B.C., Stoll G., and Hartung H.P. The role of macrophages in immune-mediated damage to the peripheral nervous system. Prog Neurobiol 64 2 (Jun 2001) 109-127
12. Mäurer M., Toyka K.V., and Gold R. Immune mechanisms in acquired demyelinating neuropathies: lessons from animal models. Neuromuscul Disord 12 4 (May 2002) 405-414
13. Kieseier B.C., Kiefer R., Gold R., Hemmer B., Willison H.J., and Hartung H.P. Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system. Muscle Nerve 30 2 (Aug 2004) 131-156
14. Hughes R.A., Raphaël J.C., Swan A.V., and Doorn P.A. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev 1 (2004) CD002063
15. Dalakas M.C. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Pharmacol Ther 102 3 (Jun 2004) 177-193
16. Enders U., Toyka K.V., Hartung H.P., and Gold R. Failure of intravenous immunoglobulin (IVIg) therapy in experimental autoimmune neuritis (EAN) of the Lewis rat. J Neuroimmunol 76 1-2 (Jun 1997) 112-116
17. Gabriel C.M., Gregson N.A., Redford E.J., Davies M., Smith K.J., and Hughes R.A. Human immunoglobulin ameliorates rat experimental autoimmune neuritis. Brain 120 Pt 9 (Sep 1997) 1533-1540
18. Norton W.T., and Poduslo S.E. Myelination in rat brain: method of myelin isolation. J Neurochem 21 4 (Oct 1973) 749-757
19. Spies J.M., Pollard J.D., Bonner J.G., Westland K.W., and McLeod J.G. Synergy between antibody and P2-reactive T cells in experimental allergic neuritis. J Neuroimmunol 57 1-2 (Mar 1995) 77-84
20. Pollard J.D., Westland K.W., Harvey G.K., Jung S., Bonner J., Spies JM., et al. Activated T cells of nonneural specificity open the blood-nerve barrier to circulating antibody. Ann Neurol 37 4 (Apr 1995) 467-475
21. Wiethölter H., and Hülser P.J. Lumbar-spinal somatosensory evoked potentials in the rat after stimulation of the tibial nerve. Exp Neurol 89 1 (Jul 1985) 24-31
22. Harvey G.K., and Pollard J.D. Patterns of conduction impairment in experimental allergic neuritis. An electrophysiological and histological study. J Neurol Neurosurg Psychiatry 55 10 (Oct 1992) 909-915
23. Heininger K., Schäfer B., Hartung H.P., Fierz W., Linington C., and Toyka K.V. The role of macrophages in experimental autoimmune neuritis induced by a P2-specific T-cell line. Ann Neurol 23 4 (Apr 1988) 326-331
24. Miyagi F., Horiuchi H., Nagata I., Kitahara S., Kiyoki M., Komoriya K., et al. Fc portion of intravenous immunoglobulin suppresses the induction of experimental allergic neuritis. J Neuroimmunol 78 1-2 (Sep 1997) 127-131
25. Hartung H.P., Schäfer B., Fierz W., Heininger K., and Toyka K.V. Ciclosporin A prevents P2 T cell line-mediated experimental autoimmune neuritis (AT-EAN) in rat. Neurosci Lett 83 1-2 (Dec 16 1987) 195-200
26. McCombe P.A., van der Kreek S.A., and Pender M.P. The effects of prophylactic cyclosporin A on experimental allergic neuritis (EAN) in the Lewis rat. Induction of relapsing EAN using low dose cyclosporin A. J Neuroimmunol 28 2 (Jul 1990) 131-140
27. Zhu J., Bai X.F., Hedlund G., Björk J., Bakhiet M., Van Der Meide P.H., et al. Linomide suppresses experimental autoimmune neuritis in Lewis rats by inhibiting myelin antigen-reactive T and B cell responses. Clin Exp Immunol 115 1 (Jan 1999) 56-63
28. Di Marco R., Khademi M., Wallstrom E., Muhallab S., Nicoletti F., and Olsson T. Amelioration of experimental allergic neuritis by sodium fusidate (fusidin): suppression of IFN-gamma and TNF-alpha and enhancement of IL-10. J Autoimmun 13 2 (Sep 1999) 187-195
29. Lin T., and Spies J. Effective prevention and treatment of experimental autoimmune neuritis with Rapamycin. J Neurol Sci 199 Suppl 1 (Jul 15 2002) S114 [Abstract]
30. Yan W.X., Taylor J., Andrias-Kauba S., and Pollard J.D. Passive transfer of demyelination by serum or IgG from chronic inflammatory demyelinating polyneuropathy patients. Ann Neurol 47 6 (Jun 2000) 765-775
31. Yan W.X., Archelos J.J., Hartung H.P., and Pollard J.D. P0 protein is a target antigen in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 50 3 (Sep 2001) 286-292
32. Hansen R.J., and Balthasar J.P. Effects of intravenous immunoglobulin on platelet count and antiplatelet antibody disposition in a rat model of immune thrombocytopenia. Blood 100 6 (Sep 15 2002) 2087-2093
33. Mimouni D., Blank M., Ashkenazi L., Milner Y., Frusic-Zlotkin M., Anhalt G.J., et al. Protective effect of intravenous immunoglobulin (IVIG) in an experimental model of pemphigus vulgaris. Clin Exp Immunol 142 3 (Dec 2005) 426-432
34. Achiron A., Margalit R., Hershkoviz R., Markovits D., Reshef T., Melamed E., et al. Intravenous immunoglobulin treatment of experimental T cell-mediated autoimmune disease. Upregulation of T cell proliferation and downregulation of tumor necrosis factor alpha secretion. J Clin Invest 93 2 (Feb 1994) 600-605
35. Saoudi A., Hurez V., de Kozak Y., Kuhn J., Kaveri S.V., Kazatchkine M.D., et al. Human immunoglobulin preparations for intravenous use prevent experimental autoimmune uveoretinitis. Int Immunol 5 12 (Dec 1993) 1559-1567
36. George J., Barshack I., Malka E., Goldberg I., Keren P., Laniado S., et al. The effect of intravenous immunoglobulins on the progression of experimental autoimmune myocarditis in the rat. Exp Mol Pathol 71 1 (Aug 2001) 55-62
37. Buchwald B., Ahangari R., Weishaupt A., and Toyka K.V. Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barré syndrome. Ann Neurol 51 6 (Jun 2002) 673-680
38. Jacobs B.C., O'Hanlon G.M., Bullens R.W., Veitch J., Plomp J.J., and Willison H.J. Immunoglobulins inhibit pathophysiological effects of anti-GQ1b-positive sera at motor nerve terminals through inhibition of antibody binding. Brain 126 Pt 10 (Oct 2003) 2220-2234
39. Basta M., and Dalakas M.C. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 94 5 (Nov 1994) 1729-1735
40. Créange A., Gregson N.A., and Hughes R.A. Intravenous immunoglobulin modulates lymphocyte CD54 and monocyte FcgammaRII expression in patients with chronic inflammatory neuropathies. J Neuroimmunol 135 1-2 (Feb 2003) 91-95
41. Abe Y., Horiuchi A., Miyake M., and Kimura S. Anti-cytokine nature of natural human immunoglobulin: one possible mechanism of the clinical effect of intravenous immunoglobulin therapy. Immunol Rev 139 (Jun 1994) 5-19
42. Simon H.U., and Späth P.J. IVIG-mechanisms of action. Allergy 58 7 (Jul 2003) 543-552
43. Kuhlmann T., Wendling U., Nolte C., Zipp F., Maruschak B., Stadelmann C., et al. Differential regulation of myelin phagocytosis by macrophages/microglia, involvement of target myelin, Fc receptors and activation by intravenous immunoglobulins. J Neurosci Res 67 2 (Jan 15 2002) 185-190